Drugs and Pharmaceuticals

Free News Articles Category: Drugs and Pharmaceuticals Industry News Articles

October 9, 2013

Paragon BioTeck Signs Exclusive Distribution Agreement with Horus Pharma for Ilast

freeNewsArticles Story Summary: Paragon BioTeck, Inc. signs a distribution agreement with Horus Pharma for rights to supply the Ilast range of its medical-grade ocular hygiene and lid care products within the United States. It begins on an exclusive basis this month….

Read More…

September 4, 2013

Heart Imaging Technologies Wins $2.5M NIH Grant for Clinical Trials

freeNewsArticles Story Summary: Heart Imaging Technologies (HeartIT), the global leader that pioneered the first FDA approved zero-footprint medical imaging workstation, announced today that it has received a $2.5M grant from the National Institutes of Health in order to develop the ‘Cloud Based Corelab of the Future.’…

Read More…

April 19, 2013

Bausch + Lomb Signs Exclusive License Agreement with Paragon BioTeck for Phenylephrine

freeNewsArticles Story Summary: Bausch + Lomb, the global eye health company and Paragon BioTeck, Inc. today announced that the companies have entered into a license agreement for Bausch + Lomb to commercialize and distribute Paragon’s phenylephrine in the United States on an exclusive basis beginning this month….

Read More…

March 7, 2013

CMI’s Paul Gondek and Alisa Hamilton to Co-Present with Deanna Schwarz of Pfizer at 2013 PRMG Annual National Conference

freeNewsArticles Story Summary: CMI and Pfizer Inc. (NYSE:PFE) will co-present ‘Engaging Stakeholders with A Story – 3 Tips to Improve Research Reporting’ at the PMRG’s upcoming National Annual Conference March 10-12, 2013 in National Harbor, Maryland….

Read More…

February 7, 2013

CMI Further Strengthens Pharmaceutical Practice with Addition of Qualitative Leader

freeNewsArticles Story Summary: CMI Research, a leader in marketing research services and insight, announced today that Beth Thompson has joined as Vice President, Qualitative Research. Thompson brings a 20-year track record of successfully conducting highly complex domestic and global marketing research….

Read More…

July 2, 2012

From Hangovers to Head Lice: What Do Head Lice and Hangovers Have in Common? CT-based Healthcare Entrepreneur George Coleman

freeNewsArticles Story Summary: In the early 1980’s George Coleman, head of Dermedics Laboratories in Bridgeport, Conn., teamed up with the former Keneric Industries to reformulate and market an over-the-counter pharmaceutical product designed to treat the symptoms of hangovers. The product, Dr. Seltzer’s Hangover Helper, went on to become the best-selling hangover remedy in the U.S. It was eventually sold to a well-known manufacturer and, after almost 20 years on the market, was discontinued when that manufacturer was sold….

Read More…

February 1, 2012

Belvidere Pharmacy, Custom Medicine Makers, Moves to New, and Even Better, Home

freeNewsArticles Story Summary: 2012 marks an important milestone for Belvidere Pharmacy. It opened new doors in its new hometown of Highland Park. When owner and President Shara Rudner, R.Ph. took the reins of the business in 1996, it was a typical retail pharmacy stocked with everything from school to surgical supplies. But from the beginning, Belvidere’s staff handled requests for compounded, or custom-made, medications from veterinarians, physicians and specialists….

Read More…

October 30, 2011

Reaction Biology Corporation Unveils Largest Kinase Profiling Data Set in Nature Biotechnology Publication

freeNewsArticles Story Summary: Reaction Biology Corporation (‘RBC’) today announced the publication in Nature Biotechnology, of the largest kinase profiling data set in the public domain, disclosing previously unknown kinase inhibition relationships. The data set was compiled from over 100,000 independent activity assays performed with RBC’s proprietary HotSpot(SM) technology….

Read More…

October 24, 2011

Reaction Biology Launches Recombinant Methyltransferase Line

freeNewsArticles Story Summary: Reaction Biology Corporation (‘RBC’), a leading contract research organization providing drug discovery services in epigenetics, today announced the rollout of a new product line, recombinant proteins for epigenetic research. RBC’s initial offerings will emphasize the histone methyltransferases (HMTs), including exclusive targets for which there has been no previous commercial source….

Read More…

February 28, 2011

Epeius Biotechnologies’ REXIN-G, a Tumor-Targeted Genetic Medicine for Metastatic Cancer, Gains Phase 3 Product Designation from the U.S. FDA

freeNewsArticles Story Summary: Epeius Bio announced today that the U.S. FDA has granted Phase 3 status for Company’s lead anti-cancer agent, Rexin-G, the first, and so far only, targeted gene delivery system developed to seek-out and destroy metastatic cancer….

Read More…